17/05/2015 - 21:14 DENVER – The use of nintedanib 150 mg twice daily has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis up to 76... More » Visit websiteField of Interest: RheumatologyCategories: RHEUM || Conference NewsFPN || ConferencesIMN || ConferencesRHEUM || NewsRHEUM || Lupus/Connective Tissue DiseasesFPN || NewsHOSP || NewsNews Feed: Internal Medicine News - Rheumatology